HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

5- nitro- 2- (2- phenylchroman- 6- yloxy)pyridine

inhibits sodium-calcium exchanger; structure in first source

Also Known As:

ORM-10103

Networked: 2 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrans: 130
    - Benzopyrans: 195
      - 5-nitro-2-(2-phenylchroman-6-yloxy)pyridine: 2
  - Pyridines: 88
    - 5-nitro-2-(2-phenylchroman-6-yloxy)pyridine: 2
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzopyrans: 195
      - 5-nitro-2-(2-phenylchroman-6-yloxy)pyridine: 2

Experts

1.	Chang, Po-Cheng: 1 article (01/2018)
2.	Chou, Chung-Chuan: 1 article (01/2018)
3.	Chu, Yen: 1 article (01/2018)
4.	Lee, Hui-Ling: 1 article (01/2018)
5.	Lin, Shien-Fong: 1 article (01/2018)
6.	Lu, Yu-Ying: 1 article (01/2018)
7.	Wen, Ming-Shien: 1 article (01/2018)
8.	Acsai, Károly: 1 article (10/2014)
9.	Kormos, Anita: 1 article (10/2014)
10.	Levijoki, Jouko: 1 article (10/2014)

Related Diseases

1.	Ischemia 10/05/2014 - "In conclusion, selective NCX inhibition by ORM-10103 is highly effective against ischemia/reperfusion induced pathologic alterations in [Ca2+]i homeostasis, however, it fails to normalize untoward arrhythmogenic changes in AP morphology." 10/05/2014 - "Efficacy of selective NCX inhibition by ORM-10103 during simulated ischemia/reperfusion." 10/05/2014 - "In this study we evaluated the effects of selective Na+/Ca2+ exchanger (NCX) inhibition by ORM-10103 on the [Ca2+]i transient (CaT), action potential (AP), and cell viability in isolated canine ventricular cardiomyocytes exposed to a simulated ischemia/reperfusion protocol performed either alone (modeling moderate low-flow ischemia) or with simultaneous strophantidine challenge (modeling more severe low-flow ischemia). " 10/05/2014 - "Following the application of ORM-10103 the detrimental effect of ischemia/reperfusion on cell viability and the reperfusion-induced increase in AP and CaT variabilities were substantially reduced, but ischemia-induced shifts in AP morphology were barely influenced. "
2.	Ventricular Premature Complexes (Premature Ventricular Contraction) 01/01/2018 - "In conclusion, highly selective NCX inhibition with ORM-10103 reduced premature ventricular beat burden but was unable to suppress secondary Ca rise, EADs development, or inducibility of TdP. " 01/01/2018 - "The results showed that ORM-10103 reduced premature ventricular beats but was unable to suppress the inducibility of TdP or EADs. "
3.	Heart Failure 01/01/2018 - "ORM-10103 had a neutral effect on the amplitude of secondary Cai rise in control and heart failure groups. "